These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 16207517)

  • 1. Stability of latanoprost in an ophthalmic lipid emulsion using polyvinyl alcohol.
    Sakai Y; Yasueda S; Ohtori A
    Int J Pharm; 2005 Nov; 305(1-2):176-9. PubMed ID: 16207517
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Formulation, stability and degradation kinetics of intravenous cinnarizine lipid emulsion.
    Shi S; Chen H; Cui Y; Tang X
    Int J Pharm; 2009 May; 373(1-2):147-55. PubMed ID: 19429300
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Results of a study comparing the stability, efficacy, and adverse effect profile of innovator formulation, latanoprost (Xalatan) ophthalmic solution 0.005%, with that of a new formulation of a latanoprost ophthalmic solution containing cyclodextrins.
    Tressler CS; Bean GW
    J Clin Pharmacol; 2008 Jan; 48(1):123-4; author response 125-6. PubMed ID: 18094225
    [No Abstract]   [Full Text] [Related]  

  • 4. Investigation of surfactants suitable for stabilizing of latanoprost.
    Ochiai A; Ohkuma M; Danjo K
    Int J Pharm; 2012 Oct; 436(1-2):732-7. PubMed ID: 22842310
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preparation and physical characterization of a novel marine oil emulsion as a potential new formulation vehicle for lipid soluble drugs.
    Cui G; Wang L; Davis PJ; Kara M; Liu H
    Int J Pharm; 2006 Nov; 325(1-2):180-5. PubMed ID: 16901663
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The stabilization mechanism of latanoprost.
    Ochiai A; Danjo K
    Int J Pharm; 2011 May; 410(1-2):23-30. PubMed ID: 21397673
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of latanoprost when stored at room temperature.
    Mochizuki H; Itakura H; Takamatsu M; Kiuchi Y
    Hiroshima J Med Sci; 2008 Jun; 57(2):69-72. PubMed ID: 18717189
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the stability, efficacy, and adverse effect profile of the innovator 0.005% latanoprost ophthalmic solution and a novel cyclodextrin-containing formulation.
    Gonzalez JR; Baiza-Duran L; Quintana-Hau J; Tornero-Montaño R; Castaneda-Hernandez G; Ortiz M; Alarcon-Oceguera F; Beltran-Loustaunau M; Cortez-Gastelum M; Garcidueñas-Mejia J; Gomez-Bastar P; Jimenez-Roman J; Korder-Ortega V; Paczka-Zapata J; Torres-Segura M; Velasco-Gallegos G
    J Clin Pharmacol; 2007 Jan; 47(1):121-6. PubMed ID: 17192510
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Short- and long-term stability assessment of a new injectable diazepam submicron emulsion.
    Levy MY; Benita S
    J Parenter Sci Technol; 1991; 45(2):101-7. PubMed ID: 2051254
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stability of latanoprost in generic formulations using controlled degradation and patient usage simulation studies.
    Velpandian T; Kotnala A; Halder N; Ravi AK; Archunan V; Sihota R
    Curr Eye Res; 2015 May; 40(6):561-71. PubMed ID: 25494824
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Concentration of latanoprost ophthalmic solution after 4 to 6 weeks' use in an eye clinic setting.
    Varma R; Winarko J; Kiat-Winarko T; Winarko B
    Invest Ophthalmol Vis Sci; 2006 Jan; 47(1):222-5. PubMed ID: 16384966
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Poly(vinyl alcohol) as emulsifier stabilizes solid triglyceride drug carrier nanoparticles in the alpha-modification.
    Rosenblatt KM; Bunjes H
    Mol Pharm; 2009; 6(1):105-20. PubMed ID: 19049318
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Flocculation of protein-stabilized oil-in-water emulsions.
    Dickinson E
    Colloids Surf B Biointerfaces; 2010 Nov; 81(1):130-40. PubMed ID: 20667698
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Preparation and in vitro and in vivo evaluation of etoposide submicro-emulsion for intravenous injection].
    Tian LL; Tang X; He HB; Wang J
    Yao Xue Xue Bao; 2007 Aug; 42(8):892-7. PubMed ID: 17944242
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adaptation and optimization of the emulsification-diffusion technique to prepare lipidic nanospheres.
    Quintanar-Guerrero D; Tamayo-Esquivel D; Ganem-Quintanar A; Allémann E; Doelker E
    Eur J Pharm Sci; 2005 Oct; 26(2):211-8. PubMed ID: 16046105
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Formulation and in vitro evaluation of a cosmetic emulsion from almond oil.
    Akhtar N; Ahmad M; - G; Masood MI; Aleem M
    Pak J Pharm Sci; 2008 Oct; 21(4):430-7. PubMed ID: 18930867
    [TBL] [Abstract][Full Text] [Related]  

  • 17. UV and storage stability of retinol contained in oil-in-water nanoemulsions.
    Park H; Mun S; Kim YR
    Food Chem; 2019 Jan; 272():404-410. PubMed ID: 30309562
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Preparation and stability of digalactosyl diglyceride as emulsifier for sub-microemulsion].
    Li X; Hu J; Zhao X; Hu H; Zhao Q; Chen D
    Zhongguo Zhong Yao Za Zhi; 2009 Sep; 34(17):2172-6. PubMed ID: 19943478
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stability of ceftazidime in 1% and 5% buffered eye drops determined with HPLC method.
    Kodym A; Hapka-Zmich D; Gołab M; Gwizdala M
    Acta Pol Pharm; 2011; 68(1):99-107. PubMed ID: 21485707
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New prostaglandin analog formulation for glaucoma treatment containing cyclodextrins for improved stability, solubility and ocular tolerance.
    Rodriguez-Aller M; Guinchard S; Guillarme D; Pupier M; Jeannerat D; Rivara-Minten E; Veuthey JL; Gurny R
    Eur J Pharm Biopharm; 2015 Sep; 95(Pt B):203-14. PubMed ID: 25960331
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.